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Abstract
Resveratrol is reported to possess chemotherapeutic properties in several cancers. In this study, we wanted to investigate
the molecular mechanisms of resveratrol-induced cell cycle arrest and apoptosis as well as the impact of resveratrol on
NAMPT and SIRT1 protein function and asked whether there are differences in hepatocarcinoma cells (HepG2, Hep3B cells)
and non-cancerous primary human hepatocytes. We found a lower basal NAMPT mRNA and protein expression in
hepatocarcinoma cells compared to primary hepatocytes. In contrast, SIRT1 was significantly higher expressed in
hepatocarcinoma cells than in primary hepatocytes. Resveratrol induced cell cycle arrest in the S- and G2/M- phase and
apoptosis was mediated by activation of p53 and caspase-3 in HepG2 cells. In contrast to primary hepatocytes, resveratrol
treated HepG2 cells showed a reduction of NAMPT enzymatic activity and increased p53 acetylation (K382). Resveratrol
induced NAMPT release from HepG2 cells which was associated with increased NAMPT mRNA expression. This effect was
absent in primary hepatocytes where resveratrol was shown to function as NAMPT and SIRT1 activator. SIRT1 inhibition by
EX527 resembled resveratrol effects on HepG2 cells. Furthermore, a SIRT1 overexpression significantly decreased both p53
hyperacetylation and resveratrol-induced NAMPT release as well as S-phase arrest in HepG2 cells. We could show that
NAMPT and SIRT1 are differentially regulated by resveratrol in hepatocarcinoma cells and primary hepatocytes and that
resveratrol did not act as a SIRT1 activator in hepatocarcinoma cells.
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Introduction
Resveratrol, a dietary polyphenol, is reported to possess both
chemopreventive and chemotherapeutic properties in several
cancers [1]. In 1997, Jang and colleagues published a seminal
paper reporting that resveratrol is able to inhibit carcinogenesis in
all three stages (initiation, promotion and progression) [2].
Resveratrol was shown to inhibit cell proliferation, induce
apoptosis and cell cycle arrest in different cancer types and cancer
cell lines [3–9]. However, only one study compared the apoptotic
effects of resveratrol on cancer and normal cells. Baarine et al.
found apoptotic effects in murine tumoral cardiac cells which were
absent in normal cardiomyocytes [8]. The molecular mechanisms
are currently not completely understood. SIRT1 has originally
been described as a target of resveratrol [10] although some of the
data are still controversial, especially concerning resveratrol acting
as SIRT1 activator in cancer cells [11–13]. SIRT1 belongs to the
NAD (Nicotinamide adenine dinucleotide) dependent histone
deacetylases, called sirtuins. SIRT1 is involved in many cellular
pathways, such as cellular survival, apoptosis, cellular stress
response and energy metabolism. An increased expression of
SIRT1 has been reported in a variety of human cancers, including
prostate, ovarian, gastric and colorectal cancer. The role of SIRT1
in tumorigenesis is still controversially discussed. SIRT1 has been
shown to act as both tumor promoter and tumor suppressor
[14,15]. SIRT1 was shown to deacetylate the tumor-suppressor
protein p53 on lysine residue 382 leading to its inhibition and
subsequent tumorigenesis [16,17]. Thus, the inhibition of SIRT1
would induce cell death of cancer cells by activating and
acetylating p53.
It is known that cancer cells have increased energy demands
because of their rapid cell proliferation and increased DNA repair
[18]. NAD is required for both processes [19] and regulates crucial
biological processes, including transcription, cell cycle progression,
DNA repair and metabolic pathways [20,21]. Therefore, cancer
cells have a higher rate of NAD turnover than normal cells. The
regeneration of intracellular NAD pools is regulated by NAMPT
(Nicotinamide phosphoribosyltransferase). NAMPT can be found
intracellularly (iNAMPT) and extracellularly (eNAMPT). Howev-
er, neither structural differences between these forms nor the
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mechanism of NAMPT secretion are known so far. As an
intracellular protein, NAMPT catalyses the rate-limiting step in
the NAD salvage pathway starting from nicotinamide and yielding
nicotinamide mononucleotide (NMN) which is then converted to
NAD [22–25]. Some cancer cells maintain intracellular NAD
levels by overexpressing NAMPT which has been shown in
different cancer types, such as colorectal and breast cancer [26–
28]. The expression and regulation of intracellular NAMPT in
hepatocarcinoma cells has not been characterized so far. NAMPT
inhibition by its highly specific inhibitor FK866 induces apoptosis
and/or autophagy in tumor cells [29–32]. Moreover, previous
studies pointed out that inhibition of NAMPT enzymatic activity
by FK866 or inhibition of SIRT1 activity decreased proliferation
and triggered cell death in cancer cells which was associated with
increased acetylation of p53 (K382) [16,17,33,34].
Here we investigated the molecular mechanisms of resveratrol-
induced apoptotic effects on hepatocarcinoma cells and non-
cancerous human hepatocytes and asked whether NAMPT and




Non-cancerous primary human hepatocytes were supplied by
the ‘‘virtual liver’’ program (German Federal Ministry of
Education and Research) and the non profit foundation HTCR,
including the informed patient’s consent. The use of human
hepatocytes for research purposes was approved by the local ethics
committee of the Charite´ University Berlin. Written informed
consent was obtained from all patients. The Charite´ University
Berlin institutional review board specifically approved this study.
Material
Cell culture media, supplements and antibiotics were obtained
from PAA (Co¨lbe, Germany) or Invitrogen (Karlsruhe, Germany).
Resveratrol (trans isomer), nicotinamide and camptothecin were
purchased from Sigma-Aldrich (Munich, Germany). FK866 was
kindly provided by TopoTarget A/S, Copenhagen, Denmark.
EX527 was obtained from Cayman Chemical (Ann Arbor, USA),
InSolution Trichostatin A (TSA) and etoposide were purchased
from Merck Millipore (Darmstadt, Germany). Flag-SIRT1
expression vector was obtained from Addgene (Addgene plasmid
1791) [35].
Cell Culture
HepG2 cells were purchased from Leibniz Institute DSMZ
(German Collection of Microorganisms and Cell cultures) and
Hep3B cell were kindly provided by Prof. Dr. Kurt Engeland
(Molecular Oncology, Medical School, University of Leipzig).
Cells were maintained in MEM medium supplemented with 10%
fetal bovine serum (FBS) and 2 mmol/L glutamine and 100 IU
penicillin and 100 mg/mL streptomycin. Primary human hepato-
cytes were isolated and cultured essentially as described [36]. Cells
were seeded in Williams’ Medium E containing 2 mmol/L
glutamine, 1027 mol/L dexamethansone, 100 IU penicillin and
100 mg/mL streptomycin and 10% FBS. All cells were grown at
37uC in a humidified atmosphere of 95% air and 5% CO2.
Cell Treatments
Resveratrol was dissolved in 100% ethanol to create a stock
solution of 100 mM. Cells were stimulated with 10/25/50/
100 mM resveratrol and the equivalent amount of solvent control
(ethanol) to exclude solvent-mediated effects. To inhibit SIRT1
and deacetylases other than histone deacetylases class III, we used
the compound EX527 [20 mM], a cell-permeable selective
inhibitor of SIRT1 dissolved in DMSO [37] and 1 mM of TSA
which were added to the incubation medium.
Measurement of Cell Viability and Apoptosis
To investigate the effects on proliferation and cell viability, we
used the commercial Cell Proliferation Reagent WST-1 (Roche,
Grenzach-Wyhlen, Germany) and measured absorbance at
450 nm. To evaluate the effects of resveratrol on apoptosis the
number of apoptotic cells was measured by flow cytometry using
the FITC Annexin V Apoptosis Detection Kit (BD Pharmingen,
Franklin Lakes, USA). Adherent and floating cells were used. 5–
10 mL of Annexin V-FITC (An) and 2 mL of propidium iodide (PI)
were added to the cell suspension. Samples were analysed using a
Beckton-Dickinson FACS LSRII. As positive control, apoptosis
was induced via camptothecin [2 mM] and etoposide [85 mM] for
24 h. An+ and double-stained An+/PI+ cells were considered
apoptotic. To exclude cytotoxic effects of resveratrol, we used
supernatant of HepG2 cells and primary human hepatocytes to
measure the release of the enzyme, adenylate kinase, from
damaged cells. Therefore, we used the ToxiLightTM Non-
destructive Cytotoxicity BioAssay Kit (Lonza, Cologne, Germany).
Cell Cycle Distribution Analysis
PI staining was used to analyse DNA content and cell cycle
distribution. After cell treatment, adherent and floating cells were
harvested and fixed with 2 mL of 70% ethanol (4uC). The cell
pellet was resuspended in 50 mL PBS with 3.3 mL RNase A
[30 mg/mL], 450 mL FACS-buffer (PBS+2% FBS) and PI
[50 mg/mL] were added to the flow cytometry tubes. Cells were
analysed using a Beckton-Dickinson FACS LSRII by measuring
the PI signal in the FL2 channel.
Table 1. Sequences of Primer and Probes used for real-time PCR (TaqMan).
Target Forward Primer Reverse Primer Probe
NAMPT GCA GAA GCC GAG TTC AAC ATC TGC TTG TGT TGG GTG GAT ATT G TGG CCA CCG ACT CCT ACA AGG TTA CTC AC
beta-ACTIN CGA GCG CGG CTA CAG CTT CCT TAA TGT CAC GCA CGA TTT ACC ACC ACG GCC GAG CGG
TBP TTG TAA ACT TGA CCT AAA GAC CAT TGCTTC GTG GCT CTC TTA TCC TCA TG AAC GCC GAA TAT AAT CCC AAG CGG TTT G
HPRT GGC AGT ATA ATC CAA AGA TGG TCA A GTC TGG CTT ATA TCC AAC ACT TCG T CAA GCT TGC TGG TGA AAA GGA CCC C
p21 CGAAGTCAGTTCCTTGTGGAG CATGGGTTCTGACGGACAT –
NAMPT (nicotinamide phosphoribosyltransferase, also known as PBEF, visfatin); p21; housekeeping genes beta-ACTIN, TBP (TATA-box-binding protein) and HPRT
(hypoxanthine phophoribosyltransferase).
doi:10.1371/journal.pone.0091045.t001
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Reverse Transcription-quantitative Real-time PCR
(RTqPCR)
To measure mRNA expression, total RNA was extracted using
the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Reverse transcription was performed
using 200 U M-MLV reverse transcriptase (Invitrogen, Karlsruhe,
Germany) per 500 ng or 1 mg total RNA with random hexamer
[p(dN)6] primers. mRNA expression was quantified by real-time
PCR with TaqMan probe based (Eurogentec, Cologne, Germany)
or SYBR green based (Primerdesign, Southampton, UK) gene
expression assay on the ABI 7500 Sequence Detection System
(Applied Biosystems, Darmstadt, Germany). The housekeeping
genes TATA-box-binding protein (TBP), hypoxanthine phosphoribosyl-
transferase (HPRT) or beta-ACTIN were quantified simultaneously.
Sequence information of primers and probes are given in Table 1.
For standardization of gene expression, the target gene amount
was normalized to the mean of the housekeeping gene expression
in each sample.
Figure 1. NAMPT and SIRT1 expression in hepatocarcinoma cells and primary human hepatocytes. A) mRNA expression and B) protein
expression of NAMPT and SIRT1 in primary human hepatocytes (n = 7), HepG2 cells (n = 8) and Hep3B cells (n = 3). Representative Western Blot is
shown out of three independent experiments. Measurement of C) intracellular NAD levels (left panel, primary hepatocytes n = 4, HepG2 cells n = 6),
basal NAMPT enzymatic activity (middle panel, primary hepatocytes n = 3, HepG2 cells n = 4) and extracellular NAMPT (eNAMPT) levels (right panel,
primary hepatocytes n= 3, HepG2 cells n = 6) in primary human hepatocytes and HepG2 cells. Data are shown as mean6 SEM. Difference between
two groups was evaluated using unpaired Student’s t-test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0091045.g001
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Protein Extraction and Immunoblotting
For protein analyses, cells were lysed in modified RIPA buffer
(50 mM TrisHCl pH 7.4; 1% NP-40; 0.25% sodium deoxycho-
late; 16Roche complete proteases inhibitor cocktail; 1 mM
EDTA; 1 mM sodium orthovanadate; 1 mM sodium fluoride;
5 mM nicotinamide; 5 mM TSA, 1 mM sodium butyrate) and
separated by SDS-PAGE (8–15%). Protein concentration of
lysates was measured by BCA protein assay (Pierce, Thermo
Scientific). After transfer to nitrocellulose membranes (Millipore,
Bedford, MA, USA), blots were blocked with 5% (w/v) non-fat dry
milk in 16TBS buffer containing 0.1% Tween 20 (TBS-T).
Primary antibodies used for immunoblotting included anti-
NAMPT clone OMNI 379 (1:5000) (Cayman Chemical, Ann
Arbor, MI, USA), anti- acetylated p53 (K382) (1:1000), anti-p53
(1:1000), anti-p53 (1C12) (1:1000), anti-phospho-p53 (Ser15)
Figure 2. Resveratrol reduces cell proliferation and induces cell cycle arrest and apoptosis in hepatocarcinoma cells which is absent
in primary human hepatocytes. Cell viability of A) primary human hepatocytes (n = 2), HepG2 and Hep3B cells (n = 3) after stimulation with
resveratrol for 24 h. Data were normalised to serum-free medium control which was set 1. B) Cell cycle distribution of HepG2 cells treated with
resveratrol for 24 h. A representative result is shown out of three independent experiments. A representative dot plot is given in Fig. S2B. C) Annexin
V/PI apoptosis assay of HepG2 (n = 3) and Hep3B cells (n = 3) treated with resveratrol for 24 h. D) A representative dot plot of the Annexin/PI staining
in HepG2 cells is shown including the mean percentage of An+ and double An+/PI+ cells of three independent experiments. Data are shown as
mean6 SEM and statistical analysis was performed using one-way ANOVA and the Bonferroni post hoc test (*p,0.05; **p,0.01 compared to serum-
free medium).
doi:10.1371/journal.pone.0091045.g002
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(1:1000), anti-SIRT1 (D379) (1:1000), anti-p21 (1:1000), anti-Bax
(1:1000), anti-caspase3 (1:500), anti- cleaved caspase3 (1:500) (Cell
Signaling, Beverly, MA, USA) and anti-GAPDH (MerckMillipore,
Schwalbach, Germany). Secondary antibodies were purchased
from DAKO (Hamburg, Germany). Immunoblotting for GAPDH
was performed to verify equivalent amounts of loaded protein.
Detection was performed using enhanced chemiluminescence.
Densitometric analysis was performed using ImageJ 1.41 Software
(NIH, USA).
Measurement of NAMPT Release
NAMPT concentration in supernatants of HepG2 cells and
primary hepatocytes was quantified using the human extracellular
NAMPT/PBEF/Visfatin ELISA Kit (AdipoGen Inc., Seoul,
South Korea), respectively, according to manufacturer’s instruc-
tions. NAMPT concentration was normalised to the correspond-
ing total protein amount in each sample. For semiquantitative
measurements, NAMPT levels were detected by using supernatant
of cultured cells for Western Blot analysis.
NAMPT Enzymatic Activity
NAMPT activity was measured by the conversion of 14C-
labelled nicotinamide to 14C-NMN using a method previously
described [38]. For preparation of lysates, cells were harvested and
resuspended in 100 mL of 0.01 mol/L sodium phosphate buffer,
pH 7.4, frozen at –80uC for 24 h and thawed at room
temperature. Cell debris was removed by centrifugation at
23,000 rcf, 90 min at 0uC. Protamine sulphate solution (1% in
NaHPO4 buffer) was added to the supernatant (70 mL/mL
supernatant) to precipitate DNA by incubation on ice for
15 min. After centrifugation at 23,000 rcf, 30 min at 0uC, aliquots
of the supernatant were stored at –80uC. Lysates (50 mg) were
added to 50 mL reaction mix (50 mmol/L TrisHCl; 2 mmol/L
ATP; 5 mmol/L MgCl2; 0.5 mmol/L PRPP; 6.2 mmol/L 14C-
nicotinamide; American Radiolabelled Chemicals, St. Louis; MO,
USA) and incubated at 37uC for 1 h. Optimal conditions for the
NAMPT activity assay (amount of total protein, incubation time,
pH value) were determined (Fig. S1A,B,C). For measuring
extracellular NAMPT activity we used supernatant of HepG2
cells and concentrated it 80-fold using Amicon Ultra Centrifugal
Filter Units (Ultracel-50k) (Millipore). Then, 10 ml of concentrated
supernatant was used for the enzyme assay reaction mix and
incubated for 2 h at 37uC. The NAMPT enzymatic reaction was
terminated by mixing with 2 mL of acetone. The mixture was
then transferred onto acetone-pre-soaked glass microfiber filters
(GF/A Ø 24 mm; Whatman, Maidstone, UK). After rinsing with
261 mL acetone, filters were dried, transferred into vials with
6 mL scintillation cocktail (Betaplate Scint, PerkinElmer, Wal-
tham, MA, USA) and radioactivity of 14C-NMN was quantified in
a liquid scintillation counter in counts per minute (cpm) (Wallac
1409 DSA, PerkinElmer). NAMPT activity was normalised to
total protein concentration as measured by the BCA protein assay.
The validity of the assay was evaluated by adding the specific
NAMPT inhibitor, FK866 (Fig. S1C). FK866 induced a dose-
dependent decrease in NAMPT activity with an IC50 value of
8.2 nM.
NAD Measurements
Concentrations of NAD from whole-cell extracts were quanti-
fied by High-performance liquid chromatography (HPLC) and the
NAD/NADH assay kit (EnzyChrom NAD/NADH Assay Kit,
Biotrend, Ko¨ln, Germany), applied according to manufacturer’s
instructions. HPLC analysis was performed with Chromaster
Purospher STAR RP-18 endcapped 3 mmHibar RT 150-3 HPLC
column (Merck). Briefly, cultured cells were extracted in 1 M
HClO4 and neutralized in 3 M K2CO3 on ice as described
previously [39]. After centrifugation for 10 min at 18,000 rcf
(4uC), the supernatant was filtered and loaded onto the column.
For NAD measurement, the HPLC was run at a flow rate of
0,4 ml/min with 100% buffer A from 0–5 min, a linear gradient
to 95% Buffer A/5% Buffer B (100% methanol) from 5–6 min,
95% Buffer A/5% Buffer B from 6–11 min, a linear gradient to
85% Buffer A/15% Buffer B from 11–12 min, 85% Buffer A/15%
Buffer B from 12–16 min, and a linear gradient to 100% Buffer A
from 16–17 min. NAD was eluted as a sharp peak at 15 min and
quantitated based on the peak area compared to a standard curve
and normalised to protein content of cultured cells.
Figure 3. Resveratrol activates apoptotic mechanisms in
hepatocarcinoma cells. Cells were treated with resveratrol or
serum-free medium (con) for 24 h. Activation of p53 through
phosphorylation at serine residue 15 and cleavage of caspase-3 in A)
HepG2 cells, B) Hep3B cells and C) primary human hepatocytes were
analysed by Western Blot. GAPDH was used as loading control. One
representative blot out of at least 3 independent experiments is shown.
doi:10.1371/journal.pone.0091045.g003
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Plasmid Transfection
Transfection was conducted using NEON Transfection System
(100 ml Kit, invitrogen) according to the manufacturer’s manual.
Briefly, HepG2 cells were splitted 1:3 one day before transfection.
Cells were transiently transfected with pECE-Flag-SIRT1 (2 mg
DNA/0.56106 cells) or the empty vector (mock-control). After
24 h of transfection, medium was changed for a further 24 h
resveratrol-containing medium at 37uC.
Statistical Analyses
Data are presented as mean 6 SEM. Data were analysed for
statistical significance by one-way analysis of variance (ANOVA)
followed by Bonferroni post hoc test. Differences between two
groups were evaluated using unpaired Student’s t-test. All analyses
were performed using GraphPad Prism 5 software (GraphPad
Software, Inc., San Diego, USA). The level of significance for all
comparisons was set at p,0.05.
Results
NAMPT and SIRT1 are Differentially Expressed in
Hepatocarcinoma Cells and Primary Human Hepatocytes
The expression levels of NAMPT and SIRT1 were evaluated
using qPCR and Western Blot analysis. Our data revealed that
NAMPT expression is lower in HepG2 (275.6%65.2%) and
Hep3B cells (284.6%60.5%) compared to non-cancerous
primary human hepatocytes (Fig. 1A,B). In contrast, the
NAD-dependent deacetylase SIRT1 is significantly higher
expressed in both cancer cell lines compared to primary human
hepatocytes (HepG2 cells 2.8-fold, Hep3B cells 2.5-fold)
(Fig. 1A,B). Intracellular NAD levels in HepG2 cells and
primary hepatocytes were not significantly different (HepG2
cells 1.960.3 mmol NAD/g protein compared to 1.760.3 mmol
NAD/g protein in primary human hepatocytes) (Fig. 1C, left
panel). A comparison of the NAMPT enzymatic activity in
HepG2 cells and primary human hepatocytes showed a 3-fold
higher (p,0.05) enzymatic activity of NAMPT in HepG2 cells
(57.267.7 cpm/mg protein6h) than in primary human hepato-
cytes (19.363.8 cpm/mg protein6h) (Fig. 1C, middle panel).
Additionally, we measured higher eNAMPT levels in the
supernatant of primary human hepatocytes (3.260.3 ng/mg
protein) than in HepG2 cells (0.460.2 ng/mg protein) (Fig. 1C,
right panel).
Resveratrol Induces Cell Cycle Arrest and Apoptosis in
Hepatocarcinoma Cells
Resveratrol has been shown to induce growth arrest and
apoptosis in many different cancer cell lines. In the present
study, we wanted to investigate whether the effects of resveratrol
are p53-dependent. Therefore, we used HepG2 cells, known to
be p53 wild-type, Hep3B cells - a p53 deficient cell line due to
a deletion of the p53 gene, and primary human hepatocytes as
non-cancerous hepatocyte control. Cells were treated with
resveratrol as described above. After 24 h, hepatocarcinoma
Figure 4. Effects of FK866 and EX527 on p53 acetylation and cell viability in HepG2 cells. Cells were stimulated with FK866 [10 nM] or
EX527+TSA [20 mM EX527+1 mM TSA] in serum-free medium (con). Cells treated with A) FK866 and expression of acetylated p53 (K382) after 24 h. B)
Cell viability of HepG2 cells after stimulation with FK866 for 48 h measured by WST-1 assay (n = 4). Data were normalised to serum-free medium (con)
which was set 1 (**p,0.01; ***p,0.001 compared to serum free medium). C) Expression of acetylated p53 (K382), p21 protein and cleavage of
caspase-3 were analysed in HepG2 cells treated with EX527+TSA for 24 h. GAPDH was used as loading control. One representative blot out of 3
independent experiments is shown.
doi:10.1371/journal.pone.0091045.g004
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cells showed a dose-dependent decrease in viability (Fig. 2A).
Resveratrol [100 mM] markedly decreased cell viability by
45.862.7% (p,0.05) in HepG2 cells and by 63.763.4% (p,
0.01) in Hep3B cells (Fig. 2A). Primary human hepatocytes
treated with the same concentrations of resveratrol exhibited no
significant changes in viability (Fig. 2A). To investigate the
cause of cell viability reduction by resveratrol, we analysed cell
cycle distribution. As shown in Fig. 2B, resveratrol [25, 50 mM]
Figure 5. Resveratrol differentially regulates NAMPT and NAD levels in HepG2 cells and primary human hepatocytes. Cells were
stimulated with resveratrol or serum-free medium (con) for 24 h. For measuring NAMPT enzymatic activity in A) HepG2 cells and (n = 4) B) primary
human hepatocytes (n = 3), 50 mg of protein lysate was used for the assay and incubated for 1 h. Counts (cpm) were normalised to mg total protein.
Lysates from C) HepG2 cells (n = 3) and D) primary human hepatocytes (n = 3) were used to measure NAMPT protein levels by Western Blot.
Determination of intracellular NAD levels in E) HepG2 cells (n = 6) and F) primary human hepatocytes (n = 4). NAD levels were normalised to total
protein amount in each sample.
doi:10.1371/journal.pone.0091045.g005
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caused an increase of cells in the S-phase ([con] 4.760.6%,
[25 mM] 21.765.1%, [50 mM] 17.062.6%, p,0.05) and in the
G2/M-phase ([con] 13.761.8%, [25 mM] 23.964.2%, [50 mM]
27.066.1%, p,0.05) and a corresponding decrease of cells in
the G1-phase. The cell cycle distribution was not significantly
modified in p53-deficient Hep3B cells (Fig. S2A), which
indicates that the resveratrol-induced cell cycle arrest is
mediated by a functional p53. However, in both hepatocarci-
noma cell lines apoptotic mechanisms were activated. As
indicated in Fig. 2C, stimulation with increasing concentrations
Figure 6. Resveratrol differentially regulates p53 acetylation and SIRT1 protein level in HepG2 cells and primary human
hepatocytes. Acetylation of p53 (K382) in A) HepG2 cells (n = 4) and B) primary human hepatocytes (n = 3) was evaluated by Western Blot.
Densitometric analysis of at least three independent experiments is shown. Data are represented as mean6 SEM and statistical analysis was
performed using one-way ANOVA and the Bonferroni post hoc test (*p,0.05, n.s. not significant). As a downstream target of acetylated and activated
p53, the expression of p21 was analysed by Western Blot. As positive control for SIRT1 inhibition, EX527+TSA was used. SIRT1 protein expression was
analysed by Western Blot in C) HepG2 cells and D) primary hepatocytes and densitometric analysis was performed. GAPDH was used as loading
control, respectively. One representative blot out of at least 3 independent experiments is shown.
doi:10.1371/journal.pone.0091045.g006
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of resveratrol led to a dose-dependent increase in the number of
apoptotic cells in HepG2 (Fig. 2C,D) and Hep3B cells (Fig. 2C).
At 100 mM resveratrol, the percentage of apoptotic cells in
HepG2 cells and Hep3B cells increased to 40.665.6% (p,0.01)
and to 32.263.7% (p,0.05), respectively.
Figure 7. Effects of resveratrol on NAMPT release and NAMPT mRNA expression. Cells were stimulated with resveratrol in serum-free
medium for 24 h. Supernatants of resveratrol treated A) HepG2 cells (n = 7) and B) primary human hepatocytes (n = 3) were used for quantifying
extracellular NAMPT protein amount using a specific eNAMPT ELISA. eNAMPT protein concentration was normalised to the total protein amount.
NAMPT mRNA expression in resveratrol treated C) HepG2 cells (n = 5) and D) primary human hepatocytes (n = 4) was quantified by qRT-PCR and
normalised to housekeeping genes. NAMPT gene expression was then related to its expression in serum-free control medium (0), which was set 1.
Data are represented as mean6 SEM and statistical analysis was performed using one-way ANOVA and the Bonferroni post hoc test (*p,0.05; ***p,
0.001; n.s. not significant). E) Supernatant of resveratrol [100 mM] or serum-free medium (con) treated HepG2 cells was used to measure NAMPT
enzymatic activity and extracellular NAMPT protein levels. Counts (cpm) measured by NAMPT enzyme assay were referred to densitometric data of
NAMPT protein levels in the supernatant of the same sample. Data were then normalised to serum-free control medium which was set 1. Data are
shown as mean6 SEM. The difference between these two groups was evaluated using unpaired Student’s t-test (***p,0.001).
doi:10.1371/journal.pone.0091045.g007
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p53 and Caspase-3 are Involved in Resveratrol-mediated
Apoptotic Effects
In HepG2 cells, resveratrol increased the phosphorylation of
p53 at residue serine 15 in a dose-dependent manner (Fig. 3A). At
high concentration of resveratrol [100 mM], we found increased
cleavage of caspase-3 (Fig. 3A). The activation of caspase-3 by
resveratrol was also increased in p53-deficient Hep3B cells even at
lower concentration [25, 50 mM] (Fig. 3B). These results indicate
that resveratrol induces caspase-3 activation in a p53-independent
manner. Then, we stimulated primary human hepatocytes with
the same concentrations of resveratrol and found no induction of
apoptosis (Fig. 3C) or cytotoxicity (Fig. S3A).
Inhibition of NAMPT and SIRT1 Activity in
Hepatocarcinoma Cells Induces Growth Arrest and
Apoptosis
Several studies have shown that the NAD metabolism is
essential for cancer cell survival and proliferation [40–42].
However, little is known about the effects of resveratrol on
NAMPT and SIRT1 activity in hepatocarcinoma cells. Human
SIRT1 targets and deacetylates the p53 tumor suppressor protein
[16,17,34]. Therefore, we investigated whether a specific inhibi-
tion of NAMPT and SIRT1 would affect cell survival and
apoptotic mechanisms. We used the specific NAMPT inhibitor
FK866 and the SIRT1 inhibitor EX527 [34]. FK866 increased
p53 acetylation (K382) (Fig. 4A) and reduced HepG2 cell viability
after 48 h (Fig. 4B). Cells treated with the SIRT1 inhibitor,
EX527, showed also increased p53 acetylation (K382), enhanced
expression of p53 downstream target p21/WAF1/Cip1 and
activation of caspase-3 (Fig. 4C).
Resveratrol Differentially Regulates NAMPT Enzymatic
Activity in Hepatocarcinoma Cells and Primary Human
Hepatocytes
Based on our findings that an inhibition of NAMPT and SIRT1
activity induced growth arrest and apoptosis in hepatocarcinoma
cells we then asked whether resveratrol would also affect NAMPT
enzyme activity as well as intracellular NAD levels. We found that
resveratrol differentially regulated NAMPT activity in hepatocar-
cinoma cells (Fig. 5A) and primary hepatocytes (Fig. 5B) without
affecting NAMPT protein expression (Fig. 5C,D). We measured a
dose-dependently decreased NAMPT activity in HepG2 cells
([100 mM] 238.9614.0%, p,0.01) (Fig. 5A) and in Hep3B cells
([100 mM] 238.569.4%, p,0.05) (Fig. S4). In contrast, NAMPT
enzymatic activity in primary hepatocytes significantly increased
by +64.7613.8% (p,0.05) after stimulation with 100 mM
resveratrol (Fig. 5B). We then measured the NAD level after
resveratrol treatment in HepG2 cells and found a trend towards
reduction ([con] 2.060.4 mmol NAD/g total protein, [100 mM]
1.560.2 mmol NAD/g total protein) (Fig. 5E). In contrast,
intracellular NAD levels in primary hepatocytes were increased
by resveratrol ([con] 1.760.3 mmol NAD/g total protein, [50 mM]
6.462.5 mmol NAD/g total protein (p,0.05), [100 mM]
5.461.7 mmol NAD/g total protein) (Fig. 5F).
Resveratrol Differentially Regulates p53 Acetylation and
SIRT1 Protein in Hepatocarcinoma Cells and Primary
Human Hepatocytes
We further addressed whether resveratrol could influence p53
acetylation at lysine residue 382, a main target site of SIRT1
[16,17,34], and demonstrated that resveratrol treatment of HepG2
cells increased acetylation of p53 ([50 mM] 12.8-fold, [100 mM]
13.4-fold) (Fig. 6A). As positive control for SIRT1 inhibition, we
used the specific SIRT1 inhibitor EX527 [34,37] (Fig. 6A). In
contrast, primary human hepatocytes from different donors
showed a trend towards reduced p53 acetylation after resveratrol
stimulation (Fig. 6B). Since the acetylation of p53 activates its
transcriptional activity, we analysed the expression of the p53
downstream target p21/WAF1/Cip1, which functions as a
regulator of cell cycle progression. In correspondence to the
acetylation state of p53 we found increased expression of p21
mRNA (Fig. S5A) and protein in HepG2 cells (Fig. 6A). Primary
human hepatocytes from different donors showed variable results
with either no changes in p21 protein expression or a p21 down
regulation (Fig. 6B, Fig. S5B). Nonetheless, we can exclude an
activation of p53 in primary human hepatocytes. Furthermore,
SIRT1 protein levels in HepG2 cells were reduced at 100 mM
resveratrol (p,0.01) (Fig. 6C) whereas primary human hepato-
cytes showed a trend towards increased SIRT1 protein expression
at the same dose of resveratrol (Fig. 6D). Due to the variability of
primary hepatocytes the changes were not significant.
Figure 8. SIRT1 inhibition downregulates NAMPT activity and induces NAMPT release in HepG2 cells. HepG2 cells were treated with
EX527+TSA [20 mM EX527+1 mM TSA] or serum-free medium (con) for 24 h. Measurement of A) NAMPT enzymatic activity (n = 3). Counts (cpm) were
normalised to mg total protein in each sample (*p,0.05). B) NAD level were determined by HPLC (n = 5) and normalised to total protein amount in
each sample. C) Supernatant of EX527 treated HepG2 cells was used for determination of eNAMPT level. One representative Western blot out of 3
independent experiments is shown.
doi:10.1371/journal.pone.0091045.g008
Resveratrol Differentially Regulates NAMPT and SIRT1
PLOS ONE | www.plosone.org 10 March 2014 | Volume 9 | Issue 3 | e91045
Figure 9. SIRT1 overexpression in HepG2 cells reversed resveratrol-induced SIRT1 inhibition, NAMPT release and S-phase arrest. A)
SIRT1 was transiently overexpressed in HepG2 cells [2.0 mg plasmid/0.5x106 cells] using the expression vector pECE_Flag-SIRT1 from addgene
(plasmid 1791; [35]). Lysates of cells transfected with the empty vector pECE (mock-control) (1) or pECE Flag-SIRT1 vector (2) were used for Western
Blot analysis. B) mock-transfected (mock-control) and Flag-SIRT1 transfected HepG2 cells were stimulated with resveratrol [50, 100 mM Resv.] for 24 h
and Western Blot analysis of acetylated p53 (K382), p21 and GAPDH was performed. Densitometric anaylsis of acetylated p53 of three independent
Western Blots is shown. Data were normalised to non-transfected HepG2 cells stimulated with resveratrol alone which was set 1. C) To analyse the
effect of SIRT1 overexpression on resveratrol-induced NAMPT release, supernatant of mock-transfected and Flag-SIRT1 transfected HepG2 cells
stimulated with or without resveratrol [100 mM] were used to measure eNAMPT level. One representative Western blot out of 3 independent
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Resveratrol Induces NAMPT Release in HepG2 Cells
Since NAMPT was found to be released from hepatocytes [43]
we determined NAMPT concentrations in supernatants from
resveratrol-treated HepG2 cells and primary hepatocytes. We
measured significantly increased amounts of extracellular
NAMPT in the supernatant of HepG2 cells treated with 50 mM
(4-fold) and 100 mM (19.8-fold) resveratrol (Fig. 7A) ([con]
0.460.2 ng NAMPT/mg total protein, [50 mM] 1.660.7 ng
NAMPT/mg total protein, [100 mM] 7.961.3 ng NAMPT/mg
total protein, p,0.001). We postulated that NAMPT mRNA
expression may be increased following resveratrol exposure in
HepG2 cells to maintain a steady-state of intracellular NAMPT
protein level. We found a significantly increased NAMPT gene
expression after stimulation with 50 mM (1.8-fold, p,0.05) and
100 mM (1.7-fold, p,0.05) resveratrol in HepG2 cells (Fig. 7C).
NAMPT release and NAMPT mRNA expression in primary
human hepatocytes were not influenced by resveratrol (Fig. 7B,D).
In parallel, a cytotoxicity assay was performed to verify that the
increase of extracellular NAMPT levels was not due to leakage
from damaged cells (Fig. S3B). We then asked at which time point
NAMPT release from HepG2 cells started. We found that there
was a time- and dose- dependent release of NAMPT already
starting after 6 h of resveratrol exposure (Fig. S3C). NAMPT is
known as a protein with dual function- an enzyme and a
cytokine-like function. We asked whether NAMPT that is
released after resveratrol exposure could lack NMN biosynthetic
action. We found a remarkable decrease in extracellular NAMPT
activity by 72.3611.9% (p,0.001) compared to control cells in
serum-free medium (Fig. 7E).
NMN does not Protect Against Resveratrol- induced
Apoptosis in Hepatocarcinoma Cells
Next, we investigated whether NMN would be able to
ameliorate resveratrol-mediated effects in HepG2 cells. Inter-
estingly, NMN did not protect from resveratrol-induced cell
cycle arrest and apoptosis in hepatocarcinoma cells (Fig.
S6A,B,C,D). Further, NMN was not able to abrogate p53
hyperacetylation after resveratrol treatment and to decrease
resveratrol-induced NAMPT release in HepG2 cells (Fig.
S6E,F).
SIRT1 Inhibition Decreases NAMPT Activity and Induces
NAMPT Release
Given that resveratrol increased p53 acetylation (K382),
downregulated NAMPT activity and induced NAMPT secre-
tion, we asked whether an inhibition of SIRT1 by EX527 would
exert the same effects. Indeed, our data revealed that HepG2
cells treated with EX527 showed the same cellular responses
as cells stimulated with resveratrol, such as decreased NAMPT
enzymatic activity (240.3611.5%, p,0.05) (Fig. 8A)
and slightly reduced intracellular NAD level (Fig. 8B).
Further, as observed in resveratrol-treated HepG2 cells,
extracellular NAMPT levels were increased upon SIRT1
inhibition (Fig. 8C).
SIRT1 Overexpression Abrogated Resveratrol- induced
p53 Hyperacetylation, NAMPT Release and S-phase Arrest
Since resveratrol and NMN co-treatment did not augment
resveratrol-induced p53 hyperacetylation in hepatocarcinoma
cells, we tried to overcome this effect by transiently overexpressing
SIRT1 in HepG2 cells (Fig. 9A). Our data revealed that SIRT1
overexpression significantly decreased resveratrol- induced p53
hyperacetylation ([50 mM] 276.666.5%, [100 mM] 2
69.9615.9%, p,0.05) and its transcriptional activity in HepG2
cells (Fig. 9B). We then investigated whether a SIRT1 overex-
pression would be able to abrogate resveratrol-induced NAMPT
secretion in HepG2 cells. SIRT1 overexpressing HepG2 cells
treated with 100 mM resveratrol led to decreased eNAMPT levels
in the supernatant compared to mock-transfected cells treated with
resveratrol alone (Fig. 9C). This suggests that SIRT1 may play a
crucial role in the mechanism of resveratrol-induced NAMPT
secretion. Reduction in cell viability upon resveratrol treatment
[100 mM] was not abolished by SIRT1 overexpression (Fig. 9D)
indicating that apoptosis inducing factors were still activated and
not dependent on SIRT1. However, the resveratrol- induced cell
cycle arrest in the S-phase was significantly decreased after SIRT1
overexpression ([con] 7.460.9%, [con+25 mM] 28.162.6%,
[Flag-SIRT1+25 mM] 18.563.8%; [con+50 mM] 26.663%,
[Flag-SIRT1+50 mM] 17.163.2%) (Fig. 9E).
Discussion
There is growing in vitro and in vivo evidence demonstrating the
inhibitory effects of resveratrol on liver cancer [44–46]. It is known
that resveratrol affects numerous signal transduction pathways
associated with tumorigenesis [47]. However, the mechanisms
how resveratrol selectively modulates proliferation and apoptosis
in tumor cells are not fully understood. A recent study
demonstrated that resveratrol has the chemical structure to inhibit
the activity of different human histone deacetylases (HDACs),
important transcriptional and post-translational regulators [48].
We investigated the molecular mechanisms of resveratrol-induced
reduction of cell viability in human hepatocellular carcinoma cells
and compared the results with non-cancerous primary human
hepatocytes. We found that resveratrol selectively induced
apoptosis in HepG2 and Hep3B cells, but not in primary
hepatocytes. Our data confirm the apoptotic effects of resveratrol
on hepatocarcinoma cells independent of p53 function. Further-
more, several other studies reported that resveratrol induced p53-
independent apoptosis in tumor cells [49,50], indicating that p53 is
not an absolute requirement for the apoptotic effect of resveratrol.
In contrast, we found an arrest of cells in the S- and G2/M-phase
of the cell cycle only in p53 wild-type HepG2 cells and not in
Hep3B cells lacking p53, which was also shown by other groups
[7,51,52].
Our study revealed that NAMPT and SIRT1 were expressed in
an opposite way in hepatocarcinoma cells and primary hepato-
cytes and were differentially regulated by resveratrol. Other
groups found SIRT1 expression to be significantly elevated in
hepatocellular carcinoma (HCC) compared to non-cancerous
tissues, the expression levels correlated with tumor grades and
experiments is shown. D) Cell viability of mock-transfected and Flag-SIRT1 transfected HepG2 cells treated with resveratrol [100 mM] (black bars) was
measured using WST-1 assay (n = 3). Data were normalised to untreated mock-control which was set 1. E) mock-transfected (white bars) and Flag-
SIRT1 transfected HepG2 cells (black bars) were stimulated with resveratrol [25, 50 mM] for 24 h. Percentage of cells in the S-phase were measured by
PI staining and FACS analysis. All data are shown as mean6 SEM (n= 4). The difference between two groups was evaluated using unpaired Student’s
t-test (##p,0.01 mock-transfected cells compared to mock-transfected cells treated with resveratrol (white bars, mock-control), **p,0.01, ***p,
0.001 Flag-SIRT1 transfected cells treated with resveratrol (black bars) compared to resveratrol-treated mock-transfected cells (white bars).
doi:10.1371/journal.pone.0091045.g009
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predicted poor prognosis. SIRT1 was shown to promote
tumorigenesis in HCC, and inhibition of SIRT1 consistently
suppressed the proliferation of HCC cells in vitro or in vivo via the
induction of cellular senescence or apoptosis [53–56]. The
expression and role of NAMPT in HCC has not been
characterised so far. In contrast to findings in other cancer cell
types [18], we found that hepatocarcinoma cells express lower
levels of NAMPT compared to non-cancerous primary hepato-
cytes. However, we found that HepG2 cells possess a higher basal
NAMPT activity than primary hepatocytes, which goes in line
with the comparable NAD levels in both cell types despite weaker
NAMPT expression in hepatocarcinoma cells.
Under basal conditions primary hepatocytes released higher
amounts of NAMPT into the supernatant than HepG2 cells. As
shown by our group, HepG2 cells and primary human hepato-
cytes constitutively release NAMPT in its dimeric, enzymatically
active form [43]. Presumably, due to the higher amount of cellular
NAMPT protein in primary human hepatocytes compared to
hepatocarcinoma cells, NAMPT is constitutively more released
from primary hepatocytes leading to higher basal eNAMPT level.
However, we cannot completely preclude, that due to necrosis of
fragile or dead primary hepatocytes, proteins are released into the
supernatant.
There are several reports showing that resveratrol acts as a
natural SIRT1 activator [10,57–60]. We observed increased
NAMPT activity and intracellular NAD levels in primary
hepatocytes providing evidence for resveratrol as SIRT1 activator
in non-cancerous cells. However, recent data showed that
resveratrol is not a direct activator of SIRT1 and therefore some
mediators are may be involved in this interplay [48,61–63].
Moreover, little is known about NAMPT and SIRT1 regulation
by resveratrol in cancer cells. A recent report showed that SIRT1
inhibition is involved in resveratrol-induced cell death in Hodgkin
lymphoma (HL)-derived L-428 cells [11]. Additionally, neuroblas-
toma cells treated with resveratrol also underwent apoptosis and
showed a downregulaton of SIRT1 [64]. In our study, resveratrol-
stimulated HepG2 cells showed similar responses like cells treated
with the SIRT1 inhibitor EX527. Thus, we assume that
resveratrol is rather acting as a NAMPT and SIRT1 inhibitor in
hepatocarcinoma cells. However, there are several reports
demonstrating other mechanisms leading to p53 acetylation by
resveratrol [65,66].
Our findings indicate that NMN did not ameliorate resveratrol-
induced effects on apoptosis, cell cycle arrest and NAMPT release,
suggesting that the availability of NAD is not a limiting factor in
this scenario. A variety of posttranslational modifications in SIRT1
N- and C-terminal extensions have been reported, effecting
SIRT1 enzyme activity and protein interactions [67,68]. Our
findings raise the possibility that, in some cases, the regulation of
SIRT1 by other proteins may be more important than NAD
availability. Increase in p53 transcriptional activity and induction
of S-phase arrest observed upon treatment with resveratrol were
abrogated upon SIRT1 overexpression. However, SIRT1 over-
expression was not able to augment reduced cell viability in
HepG2 cells under high resveratrol concentrations. Resveratrol
affects a multitude of other signal transduction pathways
associated with apoptotic mechanisms and transcriptional regula-
tion [66,69] that are still activated and not SIRT1 dependent [64].
Thus, these collective activities, rather than just a single effect, may
account for the anticancer properties of resveratrol. However, our
data give evidence that resveratrol regulates NAMPT activity in
cancer cells and non-cancerous cells. Resveratrol could regulate
NAMPT enzymatic activity by at least two hypothetical mecha-
nisms: i) by direct interaction inducing conformational changes
that lead to alterations of enzymatic activity, or ii) by inducing a
posttranslational modification of NAMPT. Our study revealed
that SIRT1 inhibition downregulates NAMPT activity and
induces NAMPT secretion. This provides the basis for further
mechanistic studies on NAMPT-SIRT1 interaction and their
regulation.
Further, we found a time- and dose-dependent NAMPT release
after resveratrol stimulation of HepG2 cells which was associated
with increased NAMPT mRNA expression. The association of
increased NAMPT release and mRNA expression has also been
shown by Kover et al. in human islets [70]. eNAMPT has been
described to act as a cytokine (as pre-B cell colony enhancing
factor, PBEF) [71] or as an adipokine (visfatin) [72,73] but also has
extracellular enzymatic function to yield NMN [74]. To our
knowledge, for the first time our data point to SIRT1 as regulator
of NAMPT secretion and NAMPT enzymatic activity in the
supernatant. We could show that the resveratrol-induced NAMPT
release was significantly reduced after SIRT1 overexpression,
indicating a crucial role for SIRT1 in resveratrol-mediated
NAMPT secretion.
In summary, our study revealed that resveratrol selectively
induced p53-independent cell death in hepatocarcinoma cells and
differentially regulated NAMPT and SIRT1 in cancer cells and
non-cancerous cells. Our data give evidence that in contrast to
normal hepatocytes, resveratrol does not act as a NAMPT and
SIRT1 activator in hepatocarcinoma cells. However, it remains to
be investigated whether NAMPT interacts with SIRT1 and how it
is regulated by resveratrol or other mediators and linked to cellular
metabolism and apoptosis. This will provide novel insights
concerning the potential of NAMPT and SIRT1 as therapeutic
targets in hepatocellular carcinoma.
Supporting Information
Figure S1 Establishment of parameters for a NAMPT
enzymatic assay. Assay conditions, such as A) protein amount,
B) pH value and C) incubation time were optimized for measuring
NAMPT enzymatic activity. D) We validated the assay perfor-
mance by adding the specific NAMPT inhibitor FK866 to the
lysate before measuring NAMPT activity. As expected, FK866
induced a dose-dependent decrease in NAMPT activity with an
IC50 value of 8.2 nM. Experiments were performed in HepG2
cells. Data are presented as mean6 SEM.
(TIF)
Figure S2 Cell cycle arrest in Hep3B and a representa-
tive dot plot of HepG2 cells. A) PI staining of cell cycle
distribution of Hep3B cells (n = 2) stimulated with different
concentration of resveratrol [25/50/100 mM] for 24 h. B) A
representative dot plot of cell cycle analysis of HepG2 cells. The
left plot shows pulse width versus area; this is the plot used to
distinguish between single cells and aggregates. Single cells have
been gated and a FL2-Area histogram has been drawn and
formatted to show only the events inside of the single cell region.
(TIF)
Figure S3 Resveratrol does not have cytotoxic effects on
HepG2 cells and primary human hepatocytes. HepG2
cells and primary human hepatocytes were stimulated with
resveratrol [10/25/50/100 mM] in serum-free medium for 24 h
and supernatant was used for the ToxiLight Non-destructive
Cytotoxicity BioAssay. A) Primary human hepatocytes (n = 3) and
B) HepG2 cells (n = 3) showed no cytotoxic effects after stimulation
with resveratrol. Data are shown as mean6 SEM. Statistical
analysis was performed using one-way ANOVA and the
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Bonferroni post hoc test (n.s. not significant). C) Supernatants of
resveratrol [100 mM] or serum-free medium (con) treated HepG2
cells after 6, 12 and 24 h were used to measure extracellular
NAMPT levels by Western Blot.
(TIF)
Figure S4 Resveratrol downregulates NAMPT enzymat-
ic activity in Hep3B cells. Hep3B cells were stimulated with
resveratrol [10/25/50/100 mM] in serum-free medium for 24 h.
NAMPT enzymatic activity was measured by the conversion of
14C- labelled nicotinamide to 14C-NMN (see Material and
Methods). Counts (cpm) were normalised to mg total protein in
each sample measured by BCA protein assay. Data are
represented as mean6 SEM and statistical analysis was performed
using one-way ANOVA and the Bonferroni post hoc test (*p,
0.05).
(TIF)
Figure S5 p21 and Bax expression in HepG2 cells and
primary human hepatocytes. HepG2 cells and primary
human hepatocytes were stimulated with resveratrol [10/25/50/
100 mM] in serum-free medium (0) for 24 h. p21 mRNA
expression in A) HepG2 cells (n = 3) and B) primary human
hepatocytes (n = 4). C) Lysates of HepG2 cells (n = 3) were used for
Western Blot analysis of Bax protein expression. GAPDH was
used as loading control. One representative blot out of 3
independent experiments is shown.
(TIF)
Figure S6 NMN does not ameliorate resveratrol-medi-
ated effects on cell viability, NAMPT activity, NAMPT
release and p53 hyperacetylation. Given that resvertarol
down-regulates NAMPT and increases p53 acetylation in
hepatocarcinoma cells which was absent in primary hepatocytes
we hypothesised that the administration of NMN, the reaction
product of NAMPT and a precursor of NAD, is able to ameliorate
the resveratrol-mediated effects by increasing SIRT1 activity. At
the beginning, we tested whether HepG2 cells are able to utilize
exogenous NMN [500 mM] and to synthesize NAD. Therefore, we
stimulated the cells with FK866 [10 nM] to inhibit NAMPT
activity and co-stimulated the cells with NMN [500 mM]. We
could show that FK866 depleted the intracellular NAD levels by2
79.463.3% in HepG2 cells which could be restored by NMN
supplementation. A) NAD levels of HepG2 cells (n = 5) treated
with the NAMPT inhibitor FK866 [10 nM] (white bars) in serum-
free medium (con) and NMN [500 mM] (black bars) for 24 h.
Annexin V/PI apoptosis assay of B) HepG2 cells (n = 3) and C)
Hep3B cells (n = 2) treated with resveratrol [25/50/100 mM] in
serum-free medium and co-stimulated with NMN [500 mM] for
24 h. An+ and An+/PI+ cells were considered apoptotic. Data are
represented as mean6 SEM. Differences between two groups
were evaluated using unpaired Student’s t-test (resvertarol (white
bar) compared to resveratrol +NMN (black bar)). Then D)
Western Blot analysis of cleaved caspase-3, E) acetylated p53
(K382) and F) eNAMPT levels in supernatant of these cells were
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